ICSR: individual case safety report
An individual case safety report (ICSR) is the report of one or more suspected adverse reactions to a medicine in a single patient at one point in time.
Also known as: adverse reaction report, ADR report, E2B report
4 min readUpdated
Reviewed by Gosia Luksza, CEO at Regunaut
At a glance
- Legal basis
- Articles 107 and 107a of Directive 2001/83/EC; GVP Module VI
- Deadlines
- 15 days for serious reactions, EU and non-EU; 90 days for non-serious reactions in the EU
- Submitted to
- EudraVigilance only, since 22 November 2017
- Format
- ICH E2B(R3), mandatory since 30 June 2022
How it works
An individual case safety report describes one or more suspected adverse reactions to a medicinal product occurring in a single patient at a specific point in time. Article 107 of Directive 2001/83/EC requires marketing authorisation holders to record every suspected adverse reaction brought to their attention, in the EU or in third countries, whether it is reported spontaneously by patients or healthcare professionals or arises in a post-authorisation study, and to submit the reportable ones electronically to EudraVigilance. Article 107a places a parallel duty on Member States for the reports they receive directly. GVP Module VI gives the detail, and Article 28 of Commission Implementing Regulation (EU) No 520/2012 sets the content of the report.
A case is valid, and the clock starts, once four elements are available: an identifiable reporter, an identifiable patient, at least one suspect medicinal product and at least one suspected adverse reaction. A reaction is serious if it results in death, is life-threatening, requires or prolongs hospitalisation, results in persistent or significant disability or incapacity, or is a congenital anomaly or birth defect. Serious reactions are submitted wherever in the world they occur; non-serious reactions only when they occur in the EU. Reports in the medical literature count. Holders must screen the literature for their substances, except that for the substances and journals covered by EMA's own literature monitoring service the Agency enters the cases.
Reports are exchanged as structured electronic messages in the ICH E2B(R3) format, which became mandatory for all submissions to EudraVigilance on 30 June 2022, with reactions coded in MedDRA. A holder sends them through its own gateway connection or enters them in the EVWEB interface, and EudraVigilance returns an acknowledgement for each message. Follow-up information is sent as a new version of the same case, not as a new case, and a report submitted in error is nullified. Holders do not send copies to national authorities: since 22 November 2017 EudraVigilance has been the single point of submission, and it makes each case available to the Member State concerned.
What goes wrong
Day zero recorded as the date the pharmacovigilance department received the case, when the clock started on the day anyone in the company or a contracted partner first held the four elements; serious cases triaged as non-serious and corrected on medical review, with the 15 days then counted from the correction; follow-up filed as a new case, which creates duplicates; cases from patient support programmes, social media and market research that never reach the safety database; negative acknowledgements left unresolved, so the case counts as never submitted; and licensing or distribution agreements with no timeline for exchanging safety data, which makes 15 days impossible to meet. Since September 2025 EMA has sent holders monthly reports on their compliance with the submission deadlines, and late reporting is a recurring inspection finding.
Timing
Day 0
The holder or a contracted partner first receives the four elements of a valid case.
Within 15 days
Serious cases submitted to EudraVigilance, whether they occurred in the EU or outside it.
Within 90 days
Non-serious cases that occurred in the EU submitted to EudraVigilance.
On new information
Follow-up sent as a new version of the same case, with the clock counted from receipt of the follow-up.
Serious suspected adverse reactions, wherever they occur, are submitted within 15 days of the day the holder gained knowledge of the event. Non-serious reactions occurring in the EU are submitted within 90 days. Day zero is the day on which the holder, including any party working under contract with it, first receives the minimum information for a valid case. When significant follow-up information arrives, the clock for the follow-up report starts again from the date of receipt.
What teams do with it in Regunaut
One job in the platform that turn on ICSR, each part of a wider workflow.
ICSR: common questions
What are the four minimum criteria for a valid ICSR?
An identifiable reporter, an identifiable patient, at least one suspect medicinal product and at least one suspected adverse reaction. Without all four the case is not valid and is not submitted, but the holder is expected to follow up to obtain the missing information and to keep a record of the attempt. The submission clock starts on the day the fourth element is received.
What is the deadline for submitting an ICSR in the EU?
Under Article 107(3) of Directive 2001/83/EC, serious suspected adverse reactions must be submitted to EudraVigilance within 15 days of the day the holder gained knowledge of them, whether they occurred in the EU or in a third country. Non-serious suspected adverse reactions that occurred in the EU must be submitted within 90 days.
Do non-serious cases from outside the EU have to be submitted?
No. Non-serious reactions occurring in third countries are not submitted to EudraVigilance as individual cases. The holder must still collect and record them, because Article 107 of Directive 2001/83/EC requires a record of all suspected adverse reactions worldwide, and they feed into signal detection and the cumulative data in the PSUR.